BCYC
Price
$6.99
Change
+$0.05 (+0.72%)
Updated
Dec 24 closing price
Capitalization
484.88M
68 days until earnings call
Intraday BUY SELL Signals
NGNE
Price
$20.07
Change
-$0.01 (-0.05%)
Updated
Dec 24 closing price
Capitalization
310.88M
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs NGNE

Header iconBCYC vs NGNE Comparison
Open Charts BCYC vs NGNEBanner chart's image
Bicycle Therapeutics
Price$6.99
Change+$0.05 (+0.72%)
Volume$96.48K
Capitalization484.88M
Neurogene
Price$20.07
Change-$0.01 (-0.05%)
Volume$55.15K
Capitalization310.88M
BCYC vs NGNE Comparison Chart in %
BCYC
Daily Signal:
Gain/Loss:
NGNE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCYC vs. NGNE commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and NGNE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (BCYC: $6.99 vs. NGNE: $20.07)
Brand notoriety: BCYC and NGNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 31% vs. NGNE: 24%
Market capitalization -- BCYC: $484.88M vs. NGNE: $310.88M
BCYC [@Biotechnology] is valued at $484.88M. NGNE’s [@Biotechnology] market capitalization is $310.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileNGNE’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • NGNE’s FA Score: 0 green, 5 red.
According to our system of comparison, both BCYC and NGNE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 2 TA indicator(s) are bullish while NGNE’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 2 bullish, 6 bearish.
  • NGNE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NGNE is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а +0.58% price change this week, while NGNE (@Biotechnology) price change was +4.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($485M) has a higher market cap than NGNE($311M). NGNE YTD gains are higher at: -12.205 vs. BCYC (-50.071). NGNE has higher annual earnings (EBITDA): -82.02M vs. BCYC (-245.86M). BCYC has more cash in the bank: 648M vs. NGNE (265M). BCYC has less debt than NGNE: BCYC (5.74M) vs NGNE (11.3M). BCYC has higher revenues than NGNE: BCYC (28.3M) vs NGNE (0).
BCYCNGNEBCYC / NGNE
Capitalization485M311M156%
EBITDA-245.86M-82.02M300%
Gain YTD-50.071-12.205410%
P/E RatioN/AN/A-
Revenue28.3M0-
Total Cash648M265M245%
Total Debt5.74M11.3M51%
FUNDAMENTALS RATINGS
BCYC vs NGNE: Fundamental Ratings
BCYC
NGNE
OUTLOOK RATING
1..100
6775
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6150
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (15) in the null industry is somewhat better than the same rating for NGNE (58). This means that BCYC’s stock grew somewhat faster than NGNE’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as NGNE (100). This means that BCYC’s stock grew similarly to NGNE’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as NGNE (97). This means that BCYC’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's Price Growth Rating (50) in the null industry is in the same range as BCYC (61). This means that NGNE’s stock grew similarly to BCYC’s over the last 12 months.

NGNE's P/E Growth Rating (100) in the null industry is in the same range as BCYC (100). This means that NGNE’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCNGNE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signal:
Gain/Loss:
NGNE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RCEYX59.500.23
+0.39%
Victory RS Large Cap Alpha Y
ATHIX25.210.05
+0.20%
American Century Heritage I
FGEAX26.76N/A
N/A
Fidelity Advisor Glbl Capital Apprec A
CMCMX9.44N/A
N/A
Conestoga Discovery Investors
GMLPX37.80-0.06
-0.16%
Goldman Sachs MLP Energy Infras Instl

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with NRIX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.72%
NRIX - BCYC
51%
Loosely correlated
+0.36%
NGNE - BCYC
49%
Loosely correlated
-0.05%
XNCR - BCYC
49%
Loosely correlated
-0.13%
RGNX - BCYC
48%
Loosely correlated
+0.77%
SYRE - BCYC
48%
Loosely correlated
-0.54%
More

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
-0.05%
BRNS - NGNE
51%
Loosely correlated
-1.07%
TSHA - NGNE
49%
Loosely correlated
+3.50%
ZNTL - NGNE
49%
Loosely correlated
+2.22%
RNAZ - NGNE
48%
Loosely correlated
-1.33%
STOK - NGNE
47%
Loosely correlated
+0.97%
More